{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:24:46Z","timestamp":1793384686623,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"am","delay-in-days":381,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006227","name":"Lawrence Livermore National Laboratory","doi-asserted-by":"publisher","award":["DE-AC52-07NA27344"],"award-info":[{"award-number":["DE-AC52-07NA27344"]}],"id":[{"id":"10.13039\/100006227","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmirs.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Imaging and Radiation Sciences"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.jmir.2019.06.051","type":"journal-article","created":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T18:28:10Z","timestamp":1565980090000},"page":"S58-S65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"S1","title":["An Appendix of Radionuclides Used in Targeted Alpha Therapy"],"prefix":"10.1016","volume":"50","author":[{"given":"Maryline G.","family":"Ferrier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valery","family":"Radchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jmir.2019.06.051_bib1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2174\/157016310793360657","article-title":"Targeting the nucleus: an overview of auger-electron radionuclide therapy","volume":"7","author":"Cornelissen","year":"2010","journal-title":"Curr Drug Discov Technol"},{"issue":"23","key":"10.1016\/j.jmir.2019.06.051_bib2","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.2174\/1568026611212230002","article-title":"Alpha-emitters for immuno-therapy: a review of recent developments from chemistry to clinics","volume":"12","author":"Huclier-Markai","year":"2012","journal-title":"Curr Top Med Chem"},{"issue":"1","key":"10.1016\/j.jmir.2019.06.051_bib3","first-page":"32","article-title":"Targeted alpha and beta radiotherapy: an overview of radiopharmaceutical and clinical aspects","volume":"42","author":"Lacoeuille","year":"2018","journal-title":"M\u00e9d Nucl"},{"issue":"2","key":"10.1016\/j.jmir.2019.06.051_bib4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11523-018-0550-9","article-title":"Alpha-emitters and targeted alpha therapy in oncology: from basic science to clinical investigations","volume":"13","author":"Makvandi","year":"2018","journal-title":"Target Oncol"},{"key":"10.1016\/j.jmir.2019.06.051_bib5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.critrevonc.2018.01.001","article-title":"Global comparison of targeted alpha vs targeted beta therapy for cancer: in\u00a0vitro, in\u00a0vivo and clinical trials","volume":"123","author":"Marcu","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.jmir.2019.06.051_bib6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1146\/annurev-bioeng-062117-120931","article-title":"Targeted and nontargeted \u03b1-particle therapies","volume":"20","author":"McDevitt","year":"2018","journal-title":"Annu Rev Biomed Eng"},{"issue":"7","key":"10.1016\/j.jmir.2019.06.051_bib7","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.2967\/jnumed.117.204651","article-title":"\u03b1-Emitters for radiotherapy: from basic radiochemistry to clinical studies\u2014part 2","volume":"59","author":"Poty","year":"2018","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.jmir.2019.06.051_bib8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/17425247.2018.1378180","article-title":"Radioimmunotherapy for delivery of cytotoxic radioisotopes: current status and challenges","volume":"15","author":"Martins","year":"2018","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.jmir.2019.06.051_bib9","doi-asserted-by":"crossref","DOI":"10.1515\/ract-2019-0005","article-title":"Radiochemical aspects of alpha emitting radionuclides for medical application","author":"Ferrier","year":"2019","journal-title":"Radiochim Acta"},{"issue":"2","key":"10.1016\/j.jmir.2019.06.051_bib10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2214\/AJR.14.12554","article-title":"Molecular targeted \u03b1-particle therapy for oncologic applications","volume":"203","author":"Wadas","year":"2014","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.jmir.2019.06.051_bib11","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3389\/fonc.2013.00324","article-title":"The potential and hurdles of targeted alpha therapy \u2013 clinical trials and beyond","volume":"3","author":"Elgqvist","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.jmir.2019.06.051_bib12","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/1874471011104030214","article-title":"Chemical and radiochemical considerations in radiolabeling with \u03b1-emitting radionuclides","volume":"4","author":"Wilbur","year":"2011","journal-title":"Curr Radiopharm"},{"key":"10.1016\/j.jmir.2019.06.051_bib13","series-title":"Encyclopedia of inorganic and bioinorganic chemistry","first-page":"1","article-title":"Actinides in medicine","author":"Birnbaum","year":"2018"},{"key":"10.1016\/j.jmir.2019.06.051_bib14","series-title":"Medical radiology. Radiation oncology","article-title":"Therapeutic nuclear medicine","author":"Baum","year":"2014"},{"issue":"5","key":"10.1016\/j.jmir.2019.06.051_bib15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1134\/S1066362214050014","article-title":"Radioisotope generators of short-lived \u03b1-emitting radionuclides promising for use in nuclear medicine","volume":"56","author":"Guseva","year":"2014","journal-title":"Radiochemistry"},{"issue":"1","key":"10.1016\/j.jmir.2019.06.051_bib16","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1039\/C3CS60304K","article-title":"Matching chelators to radiometals for radiopharmaceuticals","volume":"43","author":"Price","year":"2014","journal-title":"Chem Soc Rev"},{"issue":"2","key":"10.1016\/j.jmir.2019.06.051_bib17","first-page":"166","article-title":"Bifunctional chelates for metal nuclides","volume":"52","author":"Brechbiel","year":"2008","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"8","key":"10.1016\/j.jmir.2019.06.051_bib18","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.3390\/molecules22081282","article-title":"New insights in the design of bioactive peptides and chelating agents for imaging and therapy in oncology","volume":"22","author":"Tornesello","year":"2017","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.jmir.2019.06.051_bib19","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1021\/cr3003104","article-title":"Radiometals for combined imaging and therapy","volume":"113","author":"Cutler","year":"2013","journal-title":"Chem Rev"},{"issue":"3","key":"10.1016\/j.jmir.2019.06.051_bib20","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.3390\/molecules18033379","article-title":"Synthesis of peptide radiopharmaceuticals for the therapy and diagnosis of tumor diseases","volume":"18","author":"Jamous","year":"2013","journal-title":"Molecules"},{"issue":"8","key":"10.1016\/j.jmir.2019.06.051_bib21","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1080\/14712598.2016.1185412","article-title":"Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle","volume":"16","author":"Dekempeneer","year":"2016","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"10.1016\/j.jmir.2019.06.051_bib22","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1021\/acs.biomac.6b00929","article-title":"Dendrimers as innovative radiopharmaceuticals in cancer radionanotherapy","volume":"17","author":"Liko","year":"2016","journal-title":"Biomacromolecules"},{"issue":"5","key":"10.1016\/j.jmir.2019.06.051_bib23","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0969-8043(01)00282-2","article-title":"Evaluation of potential chelating agents for radium","volume":"56","author":"Henriksen","year":"2002","journal-title":"Appl Radiat Isot"},{"issue":"4","key":"10.1016\/j.jmir.2019.06.051_bib24","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/1758834016640494","article-title":"From palliative therapy to prolongation of survival: 223RaCl2 in the treatment of bone metastases","volume":"8","author":"Liepe","year":"2016","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jmir.2019.06.051_bib25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11912-015-0495-4","article-title":"Radionuclide therapies in prostate cancer: integrating Radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer","volume":"18","author":"Nilsson","year":"2016","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"10.1016\/j.jmir.2019.06.051_bib26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41391-017-0020-y","article-title":"Current approaches to incorporation of Radium-223 in clinical practice","volume":"21","author":"Parker","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"10.1016\/j.jmir.2019.06.051_bib27","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2174\/1874471011666180416161908","article-title":"Development of 225Ac radiopharmaceuticals: TRIUMF perspectives and experiences","volume":"11","author":"Robertson","year":"2018","journal-title":"Curr Radiopharm"},{"issue":"6","key":"10.1016\/j.jmir.2019.06.051_bib28","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0969-8043(02)00167-7","article-title":"Design and synthesis of 225Ac radioimmunopharmaceuticals","volume":"57","author":"McDevitt","year":"2002","journal-title":"Appl Radiat Isot"},{"issue":"4","key":"10.1016\/j.jmir.2019.06.051_bib29","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1021\/bc990153f","article-title":"Synthesis, conjugation, and radiolabeling of a novel bifunctional chelating agent for 225Ac radioimmunotherapy applications","volume":"11","author":"Chappell","year":"2000","journal-title":"Bioconjug Chem"},{"issue":"46","key":"10.1016\/j.jmir.2019.06.051_bib30","doi-asserted-by":"crossref","first-page":"14712","DOI":"10.1002\/anie.201709532","article-title":"An eighteen-membered macrocyclic ligand for Actinium-225 targeted alpha therapy","volume":"56","author":"Thiele","year":"2017","journal-title":"Angew Chem Int Ed Engl"},{"issue":"5","key":"10.1016\/j.jmir.2019.06.051_bib31","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2967\/jnumed.117.203539","article-title":"Targeted \u03b1-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control","volume":"59","author":"Kratochwil","year":"2018","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.jmir.2019.06.051_bib32","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/ph8030435","article-title":"Bench to bedside: stability studies of GMP produced Trastuzumab-TCMC in support of a clinical trial","volume":"8","author":"Milenic","year":"2015","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"10.1016\/j.jmir.2019.06.051_bib33","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/COC.0000000000000353","article-title":"Safety and outcome measures of first-in-human intraperitoneal \u03b1 radioimmunotherapy with 212Pb-TCMC-Trastuzumab","volume":"41","author":"Meredith","year":"2018","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jmir.2019.06.051_bib34","first-page":"182","article-title":"Exploration of a F(Ab\u2032)2 fragment as the targeting agent of \u03b1-radiation therapy: a comparison of the therapeutic benefit of intraperitoneal and intravenous administered radioimmunotherapy","volume":"33","author":"Milenic","year":"2018","journal-title":"Cancer Biother Radiopharm"},{"issue":"1","key":"10.1016\/j.jmir.2019.06.051_bib35","first-page":"101","article-title":"Thorium and actinium polyphosphonate compounds as bone-seeking alpha particle-emitting agents","volume":"24","author":"Henriksen","year":"2004","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.jmir.2019.06.051_bib36","first-page":"431","article-title":"Preparation of TH227-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability","volume":"22","author":"Larsen","year":"2007","journal-title":"Cancer Biother Radiopharm"},{"issue":"17","key":"10.1016\/j.jmir.2019.06.051_bib37","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1016\/j.bmcl.2016.07.034","article-title":"An efficient chelator for complexation of Thorium-227","volume":"26","author":"Ramdahl","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"issue":"34","key":"10.1016\/j.jmir.2019.06.051_bib38","doi-asserted-by":"crossref","first-page":"56311","DOI":"10.18632\/oncotarget.16910","article-title":"Targeted alpha therapy using a novel CD70 targeted Thorium-227 conjugate in in\u00a0vitro and in\u00a0vivo models of renal cell carcinoma","volume":"8","author":"Hagemann","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.jmir.2019.06.051_bib39","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3109\/02841869609101654","article-title":"Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates","volume":"35","author":"Zalutsky","year":"1996","journal-title":"Acta Oncol"},{"issue":"3","key":"10.1016\/j.jmir.2019.06.051_bib40","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1021\/bc200401b","volume":"23","author":"Wilbur","year":"2012","journal-title":"Bioconjug Chem"}],"updated-by":[{"DOI":"10.1016\/j.jmir.2020.11.003","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000}}],"container-title":["Journal of Medical Imaging and Radiation Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939865419304138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939865419304138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:47:19Z","timestamp":1761850039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1939865419304138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S1939865419304138"],"URL":"https:\/\/doi.org\/10.1016\/j.jmir.2019.06.051","relation":{},"ISSN":["1939-8654"],"issn-type":[{"value":"1939-8654","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Appendix of Radionuclides Used in Targeted Alpha Therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Medical Imaging and Radiation Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmir.2019.06.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc. on behalf of Canadian Association of Medical Radiation Technologists.","name":"copyright","label":"Copyright"}]}}